Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06883097 · ClinicalTrials.gov registry record · NA

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

A NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV), sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
314
Enrollment target
1
Study location

NCT06883097 is a NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 314 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06883097, a NA study of Smoking Cessation and Human Immunodeficiency Virus (HIV), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
314 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are: Participants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.

Conditions Studied

Smoking Cessation Human Immunodeficiency Virus (HIV) Cancer Prevention Tobacco Smoking Cessation; Tobacco Dependence Tobacco Abstinence Tobacco Dependence Caused by Cigarettes

Interventions

  • BEHAVIORAL Learn to Quit-HIV (LTQ-H) App
  • BEHAVIORAL QuitStart

Study Locations (1)

North Carolina

  • Wake Forest University, Implementation Science - Winston-Salem

Trial Details

FieldValue
Enrollment Target 314 participants
Start Date 2025-08-18
Est. Completion 2028-12
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06883097

The ClinicalTrials.gov registry entry for NCT06883097 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Learn to Quit-HIV (LTQ-H) App is the first listed.

NCT06883097 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06883097 about?

NCT06883097 is a clinical study titled "Quitting Matters Human Immunodeficiency Virus Hybrid Trial". The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smok...

What is the current status of trial NCT06883097?

This trial is currently recruiting. It is a NA study. The enrollment target is 314 participants. The study started on 2025-08-18. Estimated completion is 2028-12.

What conditions does trial NCT06883097 study?

This clinical trial studies the following conditions: Smoking Cessation, Human Immunodeficiency Virus (HIV), Cancer Prevention, Tobacco, Smoking Cessation; Tobacco Dependence.

What interventions are being tested in trial NCT06883097?

The interventions under investigation include: Learn to Quit-HIV (LTQ-H) App (BEHAVIORAL), QuitStart (BEHAVIORAL).

Who is sponsoring clinical trial NCT06883097?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06883097 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Smoking Cessation

All registered trials for this condition

Human Immunodeficiency Virus (HIV)

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.